**RESEARCH ARTICLE**

**β-1,3-Glucan, Which Can Be Targeted by Drugs, Forms a Trabecular Scaffold in the Oocyst Walls of *Toxoplasma* and *Eimeria***

G. Guy Bushkin, Edwin Motari, Paula Magnelli, Marc-Jan Gubbels, Jitender P. Dubey, Katarzyna B. Miska, Esther Bullitt, Catherine E. Costello, Phillips W. Robbins, and John Samuelson

Department of Molecular and Cell Biology, Boston University Goldman School of Dental Medicine, Boston, Massachusetts, USA; Department of Microbiology, Boston University School of Medicine, Boston, Massachusetts, USA; Department of Biology, Boston College, Chestnut Hill, Massachusetts, USA; Animal Parasitic Diseases Laboratory, Animal Natural Resources Institute, Agricultural Research Service, U.S. Department of Agriculture, Beltsville, Maryland, USA; Department of Physiology and Biophysics, Boston University School of Medicine, Massachusetts, USA; and Mass Spectrometry Resource and Department of Biochemistry, Boston University School of Medicine, Boston, Massachusetts, USA

**ABSTRACT**

The walls of infectious pathogens, which are essential for transmission, pathogenesis, and diagnosis, contain sugar polymers that are defining structural features, e.g., β-1,3-glucan and chitin in fungi, chitin in *Entamoeba* cysts, β-1,3-GalNAc in *Giardia* cysts, and peptidoglycans in bacteria. The goal here was to determine in which of three walled forms of *Toxoplasma gondii* (oocyst, sporocyst, or tissue cyst) is β-1,3-glucan, the product of glucan synthases and glucan hydrolyses predicted by whole-genome sequences of the parasite. The three most important discoveries were as follows. (i) β-1,3-glucan is present in oocyst walls of *Toxoplasma* and *Eimeria* (a chicken parasite that is a model for intestinal stages of *Toxoplasma*) but is absent from sporocyst and tissue cyst walls. (ii) Fibrils of β-1,3-glucan are part of a trabecular scaffold in the inner layer of the oocyst wall, which also includes a glucan hydrolyase that has a novel glucan-binding domain. (iii) Echinocandins, which target the glucan synthase and kill fungi, arrest development of the *Eimeria* oocyst wall and prevent release of the parasites into the intestinal lumen. In summary, β-1,3-glucan, which can be targeted by drugs, is an important component of oocyst walls of *Toxoplasma* but is not a component of sporocyst and tissue cyst walls.

**IMPORTANCE**

We show here that walls of *Toxoplasma* oocysts, the infectious stage shed by cats, contain β-1,3-glucan, a sugar polymer that is a major component of fungal walls. In contrast to fungi, β-1,3-glucan is part of a trabecular scaffold in the inner layer of the oocyst wall that is independent of the permeability barrier formed by the outer layer of the wall. While glucan synthase inhibitors kill fungi, these inhibitors arrest the development of the oocyst walls of *Eimeria* (an important chicken pathogen that is a surrogate for *Toxoplasma*) and block release of oocysts into the intestinal lumen. The absence of β-1,3-glucan in tissue cysts of *Toxoplasma* suggests that drugs targeted at the glucan synthase might be used to treat *Eimeria* in chickens but not to treat *Toxoplasma* in people.

Received 26 July 2012 Accepted 22 August 2012 Published 25 September 2012

Citation Bushkin GG, et al. 2012. β-1,3-Glucan, which can be targeted by drugs, forms a trabecular scaffold in the oocyst walls of *Toxoplasma* and *Eimeria*. mBio 3(5):e00258-12. doi:10.1128/mBio.00258-12.

Invited Editor Laura Knoll, University of Wisconsin—Madison Editor John Boothroyd, Stanford University

Copyright © 2012 Bushkin et al. This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported License, which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original author and source are credited.

Address correspondence to John Samuelson, jsamuels@bu.edu.

*Toxoplasma gondii* is a coccidian parasite that causes disseminated infections in persons lacking cell-mediated immunity (e.g., persons with AIDS and fetuses) (1, 2). It usually causes a transient illness in immunocompetent persons, but the parasite persists for life as tissue cysts in muscles and brain. *Toxoplasma* has three walled forms: oocysts, sporocysts, and tissue cysts (Fig. 1A) (3). Cats, the only host that contains sexual forms of *Toxoplasma*, shed oocysts in their feces. The oocyst wall, which is made by the zygote after fusion of gametes, has two distinct layers. In the environment, oocysts sporulate to form two sporocysts, each of which have a wall and contain four sporozoites. Humans and other warm-blooded animals are infected with *Toxoplasma* when they ingest sporulated oocysts that excyst in the intestine, diseminate, and form tissue cysts. Alternatively, humans and other warm-blooded animals become infected when they ingest tissue cysts present in undercooked meat. Regardless of the route of infection, *Toxoplasma* can cross the placenta and infect the fetus. Additionally, *Toxoplasma*, which is dormant in tissue cysts, may disseminate when patients lose cell-mediated immunity by poorly controlled HIV or by chemotherapy for organ transplantation.

*Eimeria* spp. are one of the most common and important parasites of livestock. Unlike *Toxoplasma*, they are host specific, and mostly, they parasitize the intestine (4, 5). Losses due to coccidiosis amount to billions of dollars worldwide. *Eimeria tenella* is the most pathogenic coccidium of chickens, and its entire life cycle is confined to the ceca, which are a pair of outpocketings at the junction of the small intestine and the colon. Medication with anticoccidials and immunoprophylaxis with live attenuated oocysts are used to control coccidiosis in poultry (6, 7). Unlike *Toxoplasma* oocysts, *Eimeria* oocysts contain four
sporocysts each with two sporozoites (Fig. 1A). Otherwise, oocysts of *Toxoplasma* and *Eimeria* are biologically similar. Oocyst and sporocyst walls of *Eimeria* and *Toxoplasma* are autofluorescent in UV light based upon the presence of Tyr-rich proteins that form dityrosines (7, 8). Oocyst walls of *Toxoplasma* also contain Cys- and His-rich proteins that are homologues of the most abundant *Cryptosporidium* oocyst wall proteins, which are called COWPs (9, 10).

The present studies originated with the prediction from whole-genome sequences of *Toxoplasma* and *Eimeria* of a β-1,3-glucan synthase and two glucan hydrolases (11, 12). β-1,3-glucan is a major component of the fungal cell wall that is recognized by Dectin-1, a lectin on the surfaces of macrophages (13, 14). Dectin-1 is a component of the innate immune system and plays an important role in the natural killer cell response to fungi (15). Inhibitors of glucan synthases (caspofungin, micafungin, and anidulafungin) called echinocandins are used to treat human infections with *Candida* and *Aspergillus* (16). The goals here were to determine which walls of *Toxoplasma* and *Eimeria* contain β-1,3-glucan (oocyst, sporocyst, and/or tissue cyst), identify structures formed by β-1,3-glucan in the parasite walls, and measure the effect, if any, of echinocandins on *Eimeria* infections of chickens.

**RESULTS**

The glucan synthases of *Toxoplasma* and *Eimeria* resemble plant, rather than fungal, enzymes. We used reverse transcriptase PCR (RT-PCR) from oocyst RNA to identify the coding sequences of the complete *Eimeria* glucan synthase gene and most of the *Toxoplasma* glucan synthase gene. The *Eimeria* glucan synthase gene is ~12,000 nucleotides long and encodes a 2,687-amino-acid protein coded from 27 exons. The *Toxoplasma* glucan synthase gene has three extra introns not present in *Eimeria* and is ~18,000 nucleotides long. The *Toxoplasma* glucan synthase is nearly the same length as that of *Eimeria* and shows 53% amino acid identity and 70% similarity with the *Eimeria* glucan synthase.

The predicted *Toxoplasma* and *Eimeria* glucan synthases contain a catalytic domain, which is also present in glucan synthases of fungi and plants (Fig. 1B). This catalytic domain includes numerous transmembrane helices at its C terminus, and there is another set of transmembrane helices that is N terminal to the catalytic domain (17, 18). A domain common to the parasite and plant glucan synthases but absent in fungal glucan synthases is present at the N terminus, suggesting recent common ancestry of the parasite and plant enzymes. In contrast, both parasite glucan synthases contain a stretch of >800 amino acids that is absent in glucan synthases of fungi and plants.

*Cryptosporidium parvum* and *Cryptosporidium hominis*, which are coccidian parasites that cause diarrhea in humans and animals, are missing all of the enzymes that make or hydrolyze β-1,3-glucan (19). These observations suggest that the oocyst walls of *Cryptosporidium* are not homologous to the oocyst walls of *Toxoplasma* and *Eimeria*, which contain β-1,3-glucan (see next section).

A *Toxoplasma* glucan hydrolase has a novel glucan-binding domain near its N terminus and is present in the oocyst wall. Like fungi and plants, *Toxoplasma* and *Eimeria* have a glucan hydrolase with a GH81 glycohydrolase domain (e.g., TgGH17 [ *Toxoplasma gondii* glucan hydrolase with a GH81 glycohydrolase domain]) and a glucan hydrolase with a GH17 domain (e.g., TgGH17) (Fig. 1C and D) (18). While TgGH17 and EtGH17 (*Eimeria tenella* glucan hydrolase with a GH17 domain) genes have a single exon, the TgGH81 and EtGH81 genes have ~30 exons. The glucanase domain of TgGH81 and EtGH81 is relatively divergent from those of plants and fungi and does not contain a C-terminal glucan-binding domain (GBD) that has been identified in the *Schizasacharomyces pombe* Eng1 (SpGBD [ *Schizosa-
The glucan-binding domain of TgGH17 and EtGH17 closely resembles that of plants rather than that of fungi, again consistent with common ancestry of the parasite and plant enzymes. In contrast, TgGH17 and EtGH17 have a unique Cys-rich domain between the N-terminal signal peptide and the catalytic domain (Fig. 1D; see Fig. S1 in the supplemental material). We speculated that this domain might be a glucan-binding domain (TgGBD [T. gondii GBD] or EtGBD [E. tenella GBD]), which we tested by making a maltose-binding protein (MBP) fusion protein in the periplasm of bacteria (where disulfides are made) (21).

The glucan-binding domain of the Schizosaccharomyces pombe glucan hydrolase that contains a GH81 domain (SpGBD) (Fig. 1C) binds to Saccharomyces cerevisiae walls that were deproteinated using NaOH (Fig. 2A). SpGBD also binds to oocyst walls, but not sporocyst walls, of Toxoplasma (Fig. 2B) and Eimeria (see Fig. S2 in the supplemental material). The putative glucan-binding domain of the Toxoplasma glucan hydrolase that contains a GH17 domain (TgGBD) (Fig. 1D and Fig. S1) also binds to NaOH-deproteinated Saccharomyces walls (Fig. 2A) and to oocyst walls, but not sporocyst walls, of Toxoplasma (Fig. 2B) and Eimeria (Fig. S2).

Polyclonal rabbit antibodies to the glucan-binding domain of the Toxoplasma glucan hydrolase (anti-TgGBD antibodies) bind to the oocyst walls, but not the sporocyst walls, of sporulated Toxoplasma (Fig. 2C). These oocysts were permeabilized by freezing and thawing, as shown by binding of the GalNAc-binding plant lectin Maclura pomifera agglutinin (MPA), which labels glycoproteins in the oocyst and sporocyst walls of Toxoplasma (Fig. 2C). In contrast, the anti-TgGBD antibodies do not bind to the oocyst walls of Eimeria. The latter result is explained by differences in the primary sequence of the glucan-binding domains of the Toxoplasma and Eimeria glucan hydrolases (see Fig. S1 in the supplemental material).

Dectin-1, which is the macrophage lectin that binds to 1,3-glucan, binds to oocyst walls, but not sporocyst walls, of both sporulated Toxoplasma (Fig. 2D) and Eimeria (see Fig. S2). Antibodies to 1,3-glucan also bind to oocyst walls, but not sporocyst walls, of both Toxoplasma (Fig. 2D) and Eimeria (see Fig. S2).

In summary, these results show that four different reagents (SpGBD, TgGBD, Dectin-1, and anti-1,3-glucan antibody), as well as antibodies to TgGBD, bind to oocyst walls, but not sporocysts, walls. These results also confirm that the unique Cys-rich domain near the N terminus of TgGH17 is a novel glucan-binding domain (TgGBD) and suggest that glucan-binding is the likely mechanism whereby the TgGH17 is targeted to the Toxoplasma oocyst wall.

The inner layer of oocyst walls of Eimeria is a trabecular scaffold. Transmission electron microscopic studies used unsporulated oocysts of Eimeria (Fig. 1A) that are much cheaper and safer to produce in chickens than are Toxoplasma oocysts in cats (22, 23). As a starting point, we compared the appearance of the oocyst wall of Eimeria with that of Saccharomyces. When ruthenium red is part of the fixative (24), the untreated wall of Saccharomyces shows...
relatively subtle differences in the granularity of its inner and outer halves (Fig. 3A), while the untreated oocyst wall of *Eimeria* has two distinct layers (Fig. 3B). The outer layer of the *Eimeria* oocyst wall is electron dense, while the inner layer is relatively electron lucent. After sonication, the two layers of the oocyst wall of *Eimeria* often separate from each other.

Negative staining performed prior to breaking oocyst walls shows that the outer layer is a relatively smooth, continuous structure, upon which oval objects are dispersed (Fig. 3C). In contrast, the inner layer of the oocyst wall is a trabecular scaffold that forms a narrow plane in the absence of sectioning (Fig. 3D). The trabeculae of the inner layer of the oocyst wall are 5 to 20 nm thick and have holes ranging from 5 to 250 nm in diameter. At high magnification, these trabeculae contain fibrils (presumably of β-1,3-glucan), which are for the most part straight and evenly spaced (Fig. 3E). Negative staining of broken *Toxoplasma* oocyst walls also reveals the presence of trabecular scaffolds, showing that these structures are not specific to *Eimeria*.

In summary, these results suggest that the continuous outer layer of the oocyst wall forms a permeability barrier, while the inner porous layer of the oocyst wall forms a structural support.

**Evidence for β-1,3-glucan in the inner layer of the oocyst wall.** Gas chromatography-mass spectrometry (GC-MS) of de-proteinated oocyst walls of *Eimeria* treated with acid to release monosaccharides reveals glucose as the major sugar present (see Fig. S3 in the supplemental material). Zymolyase, which contains a mixture of β-glucanases and protease from *Arthrobacter luteus* (a yeast-digesting bacterium first isolated from brewery sewage), completely removes the wall of *Saccharomyces* to form a spheroplast (Fig. 4A) (25). The inner layer of the *Eimeria* oocyst wall, which contains fibrils of β-1,3-glucan, is almost completely removed by zymolyase, while the outer layer of the oocyst wall becomes ruffled (Fig. 4B). In addition, the trabecular scaffolds seen by negative staining are dramatically reduced by zymolyase treatment.

Mass spectrometry shows that hexose oligomers released by zymolyase from walls of *Saccharomyces* and oocyst walls of *Eimeria* have similar sizes, while they vary slightly in relative abundance by matrix-assisted laser desorption ionization–time of flight mass spectrometry (MALDI-TOF MS) in Fig. 4C and D. These results then confirm the presence of β-hexose in the oocyst wall.

Fibrils of putative β-1,3-glucan are sometimes prominent after oocyst walls are treated with proteinase K, while the outer electron-dense layer is unaffected (Fig. 4E). Anti-TgGBD antibodies bind to the inner layer of *Toxoplasma* oocyst walls (Fig. 4F).

In summary, the inner layer of the oocyst wall of *Eimeria* is extensively removed by zymolyase treatment that entirely removes the wall of *Saccharomyces* to make spheroplasts. While β-1,3-glucan is present throughout the depth of the *Saccharomyces* walls, β-1,3-glucan appears to be part of a trabecular scaffold present in the inner layers of the oocyst walls of *Eimeria* and *Toxoplasma*.

**Inhibitors of fungal glucan synthases (echinocandins) markedly decrease recovery of *Eimeria* oocysts from infected chickens.** Echinocandins are antifungal drugs that target the β-1,3-glucan synthases of *Candida* and *Aspergillus* (16). Chickens infected with *Eimeria* were treated via a wing vein catheter with 10 mg/ml of caspofungin, micafungin, or anidulafungin on day 4 after infection, and animals were euthanized on day 6. While caspofungin has no effect on oocyst recovery from ceca, the number of oocysts recovered is decreased by 71 to 84% by micafungin and by 60 to 86% by anidulafungin (Fig. 5A). We recovered about twice as many oocysts from the ceca of chickens treated with 1 and 3 mg/kg of body weight of micafungin and anidulafungin compared to chickens treated with 10 mg/kg of drug. The oocysts recovered from treated and untreated animals labeled with anti-β-1,3-glucan antibodies and sporulate normally.

The mechanism for how echinocandins decrease oocyst recovery was suggested by histological examination of infected ceca. While *Eimeria* oocysts with stained walls are frequent in the mucosa and in crypt lumens of untreated chickens (Fig. 5B), walled oocysts are more difficult to find in echinocandin-treated ceca. In ceca of drug-treated chickens, there is also an increase in the number of *Eimeria* oocysts with large, purple-stained vesicles at their periphery (Fig. 5C and D). These large purple-stained vesicles likely are the same as wall-forming bodies that contain Tyr-rich proteins and other proteins, which are secreted onto the surfaces of zygotes to form the oocyst wall (4, 5).

These results suggest that the glucan synthase of *Eimeria*, like those of fungi, can be targeted by drugs and demonstrate the importance of β-1,3-glucan in oocyst wall formation. While fungi are killed by echinocandins, these drugs appear to arrest the development of oocyst walls of *Eimeria*, so that immature cysts remain in the mucosa and fail to be released into the crypt lumen.
Knockout experiments show that glucan synthase is not essential for tissue cyst formation by *Toxoplasma* in vitro. Tissue cysts that contain bradyzoites (slowly dividing forms) can be labeled with *Dolichos biflorus* lectin (DBL) (walls) and anti-SAG2Y antibodies (bradyzoites) (Fig. 6B) (26–28). In contrast, *in vitro* tissue cysts and brain cysts failed to be labeled with anti-/1,3-glucan antibodies and with antibodies to the glucan-binding domain of the *Toxoplasma* glucan hydrolase (anti-TgGBD antibodies), each of which intensely labels the oocyst wall of *Toxoplasma* (Fig. 2). RT-PCR with glucan synthase primers with *Toxoplasma* tachyzoite and bradyzoite mRNA led to few products, many of which contained unspliced introns.

To rule out the possibility that there may be cryptic glucan synthase activity in bradyzoites *in vitro* contributing to the tissue cyst wall of *Toxoplasma*, we knocked out the glucan synthase gene in an RH strain of *Toxoplasma* in which both the Ku80 and the...
These results strongly suggest that the same way as nontransformed in vitro walls can be labeled with the same set of probes for synthase and glucan hydrolases as (29). These glucan synthase knockouts (model for Toxoplasma, each composed of trabecular scaffolds. We were able to use and the inner layers of oocyst walls of Toxoplasma to demonstrate release of glucose oligomers by zymolyase from ria 6

FIG 6 Knockout experiments show that glucan synthase is not essential for tissue cyst formation by Toxoplasma in vitro. (A) PCR products for the HXGPRT gene in the glucan synthase locus are present in the glucan synthase knockout (ΔTgGS), but not in nontransformed Toxoplasma (wild type [WT]). Conversely, the Toxoplasma glucan synthase gene (TgGS) is present in nontransformed parasites, but not in the ΔTgGS parasites. (B) In vitro tissue cysts from nontransformed Toxoplasma are labeled with DBL (green walls), while nuclei are labeled with DAPI (blue). (C) ΔTgGS in vitro tissue cysts show labeling of walls with DBL similar to that of nontransformed tissue cysts shown in panel B, (D) ΔTgGS bradyzoites within an in vitro tissue cyst are labeled with anti-SAG2Y antibody similarly to nontransformed bradyzoites.

purified oocyst walls and to show that echinocandins markedly reduce oocyst release from ceca from infected chickens.

The inner layer of the oocyst wall has a trabecular appearance, which suggests that it is a scaffold that supports the outer wall and is not part of the permeability barrier that is formed by the outer layer of the oocyst wall. While a scaffold function for β-1,3-glucan is also important in fungal walls, the trabecular appearance of the inner layer of the oocyst wall is distinct. The importance of β-1,3-glucan to the formation of the oocyst wall is shown by inhibitor studies with micafungin and anidulafungin that blocked oocyst release from chickens infected with Eimeria. While we expected that echinocandin treatment would result in the release of oocysts with defective walls, we found instead that oocysts without a complete wall remained within the intestinal epithelium. Tyr-rich proteins that form dityrosine bonds likely contribute to the stability of oocyst walls, as shown for the spore walls of Saccharomyces (7, 8, 30).

Some negative results here have important implications for our understanding of these parasites and their potential control. The absence of β-1,3-glucan in the walls of sporocysts and tissue cysts suggests the presence of another yet-to-be-identified component in the walls of infectious stages of these Toxoplasma and Eimeria that make them hard, impenetrable, and resistant to stomach acids and intestinal proteases. The absence of β-1,3-glucan in tissue cysts suggests that (i) Dectin-1 is not involved in human innate and acquired immune responses to Toxoplasma and (ii) drugs hypoxanthine-xanthine-guanine phosphoribosyltransferase genes have been knocked out (RH ΔHGPRT ΔKu80) (Fig. 6A) (29). These glucan synthase knockouts (ΔTgGS) form tissue cysts in vitro that are labeled with DBL and anti-SAG2Y antibodies in the same way as nontransformed Toxoplasma (Fig. 6C and D). These results strongly suggest that β-1,3-glucan is not a component of the tissue cyst cytoskeleton, as has also been shown for sporocysts (Fig. 2). Because Toxoplasma loses its sexual competence quickly when it is passed in culture, we were not able to knock out the glucan synthase gene in a strain of Toxoplasma that infects cats and forms oocysts.

DISCUSSION

With regard to β-1,3-glucan, Eimeria oocysts appear to be a good model for Toxoplasma, because Eimeria contains similar glucan synthase and glucan hydrolases as Toxoplasma, Eimeria oocyst walls can be labeled with the same set of probes for β-1,3-glucan, and the inner layers of oocyst walls of Eimeria and Toxoplasma are each composed of trabecular scaffolds. We were able to use Eimeria to demonstrate release of glucose oligomers by zymolyase from

FIG 5 Echinocandins arrest the development of oocyst walls of Eimeria in the ceca of infected chickens. (A) Oocyst recoveries are markedly reduced versus untreated chickens in chickens treated with 10 mg/kg anidulafungin or 10 mg/kg micafungin. Error bars show standard deviations of the oocyst counts in two experiments in which there were two chickens per group. (B) Hematoxylin-and-eosin-stained section of the cecum of an untreated chicken infected with Eimeria shows zygotes in numerous developmental stages, including some with small secretory vesicles (early), large secretory vesicles near the periphery (later), and darkly stained walls (fully developed and often released into the lumen of the crypt) (arrows). (C) A cecum from a chicken treated with anidulafungin shows numerous zygotes that are arrested, so few walled forms are present. Similar results were observed with micafungin. (D) High-power view of panel C shows large purple secretory vesicles at the periphery of developing oocysts arrested by anidulafungin (arrows).
targeting glucan synthase cannot be used to remove residual cysts from persons previously infected with *Toxoplasma*. The apparent resistance of *Eimeria* to one echinocandin (castafungin) that inhibits fungal glucan synthases suggests the possibility that a glucan synthase inhibitor might be found to prevent or treat *Eimeria* infections in chickens that would not induce resistance by fungi to echinocandins.

**MATERIALS AND METHODS**

**Parasites and animals.** All animal work was approved by Institutional Animal Care and Use Committee at Boston University and the USDA. Three-week-old Sexual chickens (USDA) or 6-week-old chickens (Boston University) were infected with 75,000 sporulated oocysts of *Eimeria tenella*. *Eimeria* oocysts were recovered using a blender from ceca of euthanized chickens, filtered through gauze cloth, purified by flotation on saturated NaCl solution three times, washed three times in water, resuspended in phosphate-buffered saline (PBS), and stored at 4°C in PBS for short periods or in 1% K2Cr2O7 in PBS for long periods (22). Some oocysts were sporulated by incubation at 30°C for 48 to 72 h with agitation and then stored at 4°C or used for infections.

To determine whether echinocandins had any effect on oocyst production, we treated two or three chickens each on day 4 after *Eimeria* infection with 10 mg of caspofungin, micafungin, or anidulafungin per kg of body weight in 500 μl of saline that was injected via a catheter into a wing vein. On day 6 (2 days after drug treatment), the chickens were euthanized and *Eimeria* oocysts were recovered as described above, counted, and examined by fluorescence and transmission electron microscopy. Two birds each were also treated with 1 and 3 mg/kg micafungin and anidulafungin.

*Toxoplasma gondii* oocysts were obtained from the feces of parasite-free, 10- to 16-week-old kittens that were infected at the USDA with tissue cysts from the brains of Swiss Webster mice infected with the VEG strain of *Toxoplasma gondii* (23). The oocysts were separated from cat feces by flotation in sucrose solution. The oocysts were incubated at room temperature in 2% sulfuric acid for 1 week, and sporulated oocysts were stored at 4°C. To obtain unsporulated oocysts, we euthanized infected kittens, and unsporulated oocysts were recovered from rectal contents, floated in cold sucrose solution, and stored at 4°C in 2% sulfuric acid to prevent sporulation. The oocysts were transported cold from the USDA to Boston.

Tissue cysts of Pru strain of *Toxoplasma* in mouse brains of C57BL/6 mice were a generous gift from Jeroen Saiej of the Massachusetts Institute of Technology.

**Molecular biology and biochemistry.** A *Toxoplasma* gene encoding putative glucan synthase (TGVEG_028810) was downloaded from Toxodb and compared with an *Eimeria* gene encoding glucan synthase (ETH_00000330) using TBLASTX that highlights amino acid sequences common to each parasite protein (11, 12). Reverse transcriptase PCR (RT-PCR) with numerous primers that spanned groups of predicted exons were used to amplify coding sequences for glucan syntheses from mRNA from unsporulated oocysts of *Toxoplasma* and *Eimeria*. Predicted glucan synthases were compared with each other and with glucan synthases of fungi and plants, conserved domains and transmembrane helices were identified (17, 18), and sequences common to the parasite and plant enzymes were determined by multiple sequence alignments.

The predicted glucan hydrolase of *Toxoplasma* that contained a single exon product and a GH17 glucan hydrolase domain (TGGH17) (TGVEG_0198140) was compared to the *Eimeria* glucan hydrolase (Supercontig_1 19950 to 198146). A putative Cys-rich, glucan-binding domain of TGGH17 (TGgBD), which was between the signal peptide and the catalytic domain (see Fig. S1 in the supplemental material), was cloned into the pMAL-p5X (New England Biolabs, Ipswich, MA) vector for expression in the bacterial periplasm (21). A maltose-binding protein (MBP) fusion protein (MBP-TgGBD) was expressed in the periplasm of NEB Express Escherichia coli (New England Biolabs). MBP-TgGBD was conjugated to Alexa Fluor dyes (Invitrogen, Grand Island, NY) and used to label fungal and oocyst walls and to make a polyclonal rabbit antibody (anti-TgGBD) (Strategic Diagnostics, Inc., Newark, DE). The Schizosaccharomyces pombe Eng1 glucan-binding domain (SpGBD) was cloned, expressed, and used for fluorescence microscopy in the same way. A plasmid encoding Dectin-1 received from Gerald Fink of the Massachusetts Institute of Technology was transformed into *E. coli*. Dectin-1, which formed an inclusion body in the bacterial cytosol, was renatured and labeled with Alexa Fluor dye.

The second glucan hydrolase of *Toxoplasma*, which contains a portion of a GH81 glycohydrolase domain (TGgGH81), was roughly predicted by comparing syntenic sequences of *Toxoplasma* and *Eimeria* chromosomes using TBLASTX.

*Toxoplasma glucan synthase gene knockout (ΔTgGS) and in vitro tissue cysts. T. gondii* of the RH strain, which has a deletion of hypoxanithine-xanthine-guanine phosphoribosyltransferase (HXGPRT) (30) for use as a selectable marker and a deletion of Ku80 (29) to prevent nonhomologous DNA recombination (RH ΔHXGPRT ΔKu80), were used as parental strains for glucan synthase knockouts (ΔTgGS). A knockout construct, which consists of an HXGPRT gene flanked by a 500-nucleotide (nt) sequence upstream of the *Toxoplasma* glucan synthase gene and 500-nt sequence downstream of it, was cloned into a gateway pTKO2 destination vector (a generous gift of Jeroen Saiej of the Massachusetts Institute of Technology) using LR clonase (Invitrogen) (31). Upstream and downstream sequences were cloned into pDONR vectors using BP clonase (Invitrogen). Five-hundred-nucleotide sequences from the 5′ untranslated region (5′ UTR) and 3′ UTR of TgGS were amplified by PCR. Twenty-five micrograms of the knockout construct was transfected into freshly lysed parasites as previously described (32). Selection began one day after transfection, using 25 μg/ml mycophenolic acid and 50 μg/ml xanthine. After 10 to 14 days, parasites were tested for the absence of the glucan synthase gene by PCR using a primer set specific to the deleted area and an antisense primer within the HXGPRT marker and sets of gene-specific primers. Parasites were cloned in 384-well plates, and glucan synthase gene knockout was confirmed as described above. A single cell clone of the ΔTgGS knockout was used in subsequent experiments.

Differentiation of tachyzoites to bradyzoites and tissue cyst production in human foreskin fibroblasts were induced by making the medium alkaline in the absence of CO2 (26). The formation of tissue cysts was confirmed by light microscopy and by fluorescence microscopy using Dolichos biflorus lectin (DBL) and anti-SAG2 antibodies (27, 28).

**Mass spectrometric identification of β-glucan in oocyst walls.** Saccharomyces cerevisiae cells and T. gondii unsporulated oocysts were broken using glass beads at 4°C in a bead beater for 2 min and then washed twice in PBS. The oocyst walls were deproteinated by incubation with 1 N NaOH at 90°C for 1 h and washed three times in PBS. Prior to zymolysis treatment, oocyst walls were resuspended in α-amylase buffer (100 mM potassium phosphate [pH 6.5]) and incubated with 400 units of α-amylase at 30°C overnight with shaking to remove starch. The oocyst walls were washed three times in PBS, resuspended in zymolysis buffer (10 mM 2-mercaptoethanol, 50 mM potassium phosphate [pH 7.5]), incubated with 5 units zymolysis (Zymo Research, Irvine, CA) at 30°C overnight with shaking, and washed three times in PBS (25). Alternatively, control organisms were treated with α-amylase only. Partially digested walls were then separated from solubilized material by centrifugation at 13,000 × g for 10 min at 4°C.

The supernatants were removed, dried in a Speed-Vac, and kept at −20°C until analysis by matrix-assisted laser desorption ionization–time of flight mass spectrometry (MALDI-TOF MS) or electrospray ionization–mass spectrometry (ESI-MS). Before being subjected to mass spectral analysis, dried *Eimeria* walls were solubilized in a glass tube with 100 μl of a suspension of dimethyl sulfoxide (DMSO) over crushed NaOH pellets, and incubated at room temperature (RT) for 30 min with vortexing to initiate permethylylation. Next, 50 μl of iodomethane was added, and
the tube was vortexed. After 1 h at RT, the permeabilization procedure was repeated once by adding 100 μl of DMSO-NaOH plus 50 μl of iodomethane and incubating the suspension for another hour. To stop the reaction, 600 μl of water was added, and the permeabilized carbohydrates were extracted with 1 ml of CHCl₃. The organic phase was recovered, washed five times with 2 ml CHCl₃-H₂O (1:1), and dried under vacuum. The permeabilized samples were dissolved as described above and spotted on a MALDI-MS target plate after being mixed 1:1 with a 10-mg/ml 2,5-dihydroxybenzoic acid (DHB) matrix that had been dissolved in the same solvent. MALDI-TOF mass spectra were obtained on a Bruker Daltonics Reflex IV (Bruker Daltonics, Billerica, MA) mass spectrometer operated in the positive-ion reflectron mode. The spectra resulting from 150 and 200 shots from a 337-nm nitrogen laser were summed. The laser pulse width was 3 ns.

For monosaccharide analysis, walls of T. tenella that had been deproteinized by treatment with NaOH were dissolved in 500 μl of 1 M methanolic-HCl at 80°C for 16 h. Sugars were trimethylsilylated in 200 μl of N,O-bis-(trimethylsilyl)-trifluoroacetamide (BSTFA) at 80°C for 45 min. GC-MS analysis was performed on a 6890 series GC-MS system instrument (Agilent, Santa Clara, CA). Sample retention times and mass spectral fragmentation patterns were then compared with those of hecose standards.

**Mass fluorescence microscopy.** Toxoplasma and *Eimeria* oocysts were purified on a three-step CaCl gradient (ρ = 1.05, 1.1, and 1.15) by ultracentrifugation at 16,000 × g for 1 h, washed in PBS, and permeabilized by four cycles of freeze-thawing. Permeabilized oocysts were incubated with 2 μg/ml Alexa Fluor-labeled Dectin-1, SpGBD, or TgGBD in PBS plus 1% bovine serum albumin (BSA) for 1 h at RT and then washed three times in PBS. Alternatively, oocysts were incubated with rabbit anti-β-glucan (a gift from Gerald Fink) or anti-TgGBD antibodies, washed twice in PBS, and then incubated with Alexa Fluor-labeled anti-rabbit antibodies for another hour and washed three times. Alexa Fluor-labeled Macluracarpus pomifera agglutinin (MPA), which binds to sporocyst walls, and cyanovin-N, which binds to sporozoites, were used at 2 μg/ml to verify permeability (9, 33). In cases where *Eimeria* oocysts were deproteinized, oocysts were incubated for 1 h in 1 N NaOH at 90°C, washed three times in PBS, and labeled as described above.

**Toxoplasma gondii** wild-type and glucan synthase knockout (ΔTgGS) tissue cysts grown on glass coverslips were fixed in 4% paraformaldehyde for 30 min at RT, washed three times in PBS, permeabilized with 0.1% Triton X-100 for 10 min, and then washed three times in PBS. Tissue cysts were incubated with 2 μg/ml of anti-SAG2Y antibody (a gift from John Boothroyd of Stanford University) in 1% BSA in PBS for 1 h at RT, washed three times in PBS, incubated with Alexa Fluor-labeled anti-mouse antibody in 1% BSA in PBS for another hour at RT, and then washed three times in PBS (28). Alternatively, tissue cysts were fixed and permeabilized in methanol for 10 min, washed three times in PBS, incubated in 1% BSA in PBS for 1 h at RT with Alexa Fluor-labeled DAPI at 2 μg/ml and then washed three times in PBS (27). The nuclei of host and *Toxoplasma* cells were labeled by 2 μg/ml DAPI (4',6'-diamidino-2-phenylindole) in PBS for the last 10 min of antibody or lectin labeling.

Slides were examined by three-dimensional multiple-wavelength fluorescence microscopy using an Olympus IX70 microscope equipped for DELTAVIS deconvolution (Applied Precision, Issaquah, WA). This system employs restorative and deconvolution techniques. The images were collected at 0.2-mm optical sections for the indicated wavelengths and were subsequently deconvolved using SoftWoRx (Applied Precision). Data were examined either as optical sections or as a projection of the entire stack.

**TEM.** For negatively stained transmission electron microscopy (TEM), *Eimeria* and *Toxoplasma* unsporulated oocysts were either left untreated or treated with zymolase. For untreated samples, unsporulated oocysts were broken with glass beads in a glass bead beater for 2 min at 4°C with protease inhibitor cocktail (Roche Applied Science, Madison, WI) and then washed three times in PBS. For zymolase treatment, unsporulated oocysts were broken and washed as described above, resuspended in α-amylase buffer incubated with 400 units of α-amylase at 30°C overnight, washed in PBS, incubated with 5 units of zymolase at 30°C overnight, and washed in PBS.

The samples were then incubated in 0.1% ruthenium red for 5 min, loaded onto carbon-coated EM grids, washed in 20 mM Tris, stained with 1% uranyl acetate (UA) for 5 min, washed in Tris, and then stained again with UA. Alternatively, in order to visualize the outer layer alone, unsporulated oocysts were first incubated with ruthenium red, washed three times in PBS, stained with UA, washed three times in PBS, and then broken and washed as described above before they were loaded on grids. Images were recorded at 120 kV in a Philips CM12 transmission electron microscope on Kodak SO163 film and scanned on a Nikon 9000 scanner.

For thin-section TEM, *Eimeria* unsporulated oocysts and Saccharomyces cells were left untreated, sonicated (*Eimeria*), or broken with glass beads at 4°C (yeast), before washing with PBS and deproteinizing with 1 N NaOH at 90°C for 1 h. Alternatively, intact yeast and sonicated oocysts were treated with 5 units of zymolase at 30°C overnight and washed in PBS. Alternatively, sonicated oocysts were incubated with 40 μg proteinase K (Invertogen) in 250 μl PBS at 50°C overnight and then washed in PBS.

Treated and untreated oocysts and yeast were fixed in 2.5% paraformaldehyde, 5% glutaraldehyde, and 0.06% picric acid in 200 mM cacodylate buffer for 1 h. Organisms were postfixed for >12 h at 4°C in 1% osmium tetroxide in the presence of 0.1% ruthenium red in cacodylate buffer (24). Water was removed from pellets in a graded series of solutions of ethanol and propylene oxide, and organisms were embedded in Epon at the Harvard Medical School Electron Microscopy Facility. Ultrathin sections (60 to 80 nm) were cut on a Reichert Ultracut-S microtome, picked up and placed on copper grids, and stained with 1% UA and 0.2% lead citrate, and images were recorded at 80 kV in a JEOL 1200EX transmission electron microscope using DITABIS digital imaging.

For immunoelectron microscopy, oocysts of *Toxoplasma* were fixed in 2% paraformaldehyde and 0.1% glutaraldehyde, dehydrated, and embedded in LR White resin. Ultrathin sections were picked up on copper grids, which were incubated with rabbit anti-TgGBD antibodies. Rabbit antibodies were localized using protein A-gold. Control incubations omitted the anti-TgGBD antibody.

**SUPPLEMENTAL MATERIAL**

Supplemental material for this article may be found at http://mbio.asm.org/lookup/ suppl/doi:10.1128/mBio.00258-12/-/DCSupplemental.

Figure S1, TIF file, 2.4 MB.

Figure S2, TIF file, 2.4 MB.

Figure S3, TIF file, 0.3 MB.

**ACKNOWLEDGMENTS**

We thank Rudi Beiler and Kath Hardcastle of the Boston University Lab of Health (NIH) (grant AI48082 to J.S., grant AI07642 [T32] to G.G.B., and grant GM31318 to P.W.R.). This work was also supported by grants RR010888, GM104603, and RR015942 to C.E.C., grant AI081924 to the University for help with electron microscopy. We thank Raymond Fletterer and Ruth Barfield of the USDA for their guidance in *Eimeria* chicken infections. We thank Maria Ericson of the Harvard Medical School for help with electron microscopy.

This work was supported in part grants from the National Institutes of Medicine (NIH) (grant AIH8082 to J.S., grant AI07642 [T32] to G.G.B., grants RR10888, GM104603, and RR105942 to C.E.C., grant AI081924 to M.-J.G., and grant GM31318 to P.W.R.). This work was also supported in part by the United States Department of Agriculture (USDA) (CRIS 1265-31320-075-00D to K.B.M.).

**REFERENCES**

1. Boothroyd JC. 2009. *Toxoplasma gondii*: 25 years and 25 major advances for the field. Int. J. Parasitol. 39:935–946.

2. Weiss LM, Dubey JP. 2009. Toxoplasmosis: a history of clinical observations. Int. J. Parasitol. 39:895–901.

3. Dubey JP, Lindsay DS, Speer CA. 1998. Structures of *Toxoplasma gondii*.
tachyzoites, bradyzoites, and sporozoites and biology and development of tissue cysts. Clin. Microbiol. Rev. 11:267–299.
4. Belli SI, Smith NC, Ferguson DJ. 2006. The coccidian oocyst: a tough nut to crack! Trends Parasitol. 22:416–423.
5. Ferguson DJ, Belli SI, Smith NC, Wallach MG. 2003. The development of the macrogamete and oocyst wall in *Eimeria maxima*: immuno-light and electron microscopy. Int. J. Parasitol. 33:1329–1340.
6. Chapman HD, Jeffers TK, Williams RB. 2010. Forty years of monensin for the control of coccidiosis in poultry. Poult. Sci. 89:1788–1801.
7. Sharan MA, Smith NC, Wallach MG, Katri M. 2010. Chasing the golden egg: vaccination against poultry coccidiosis. Parasite Immunol. 32:590–598.
8. Fritz HM, Bowyer PW, Bogyo M, Conrad PA, Boothroyd JC. 2012. Proteomic analysis of fractionated *Toxoplasma* oocysts reveals clues to their environmental resistance. PLoS One 7:e29955.
9. Chatterjee A, et al. 2010. Evidence for mucin-like glycoproteins that tether sporozoites of *Cryptosporidium parvum* to the inner surface of the oocyst wall. Eukaryot. Cell 9:84–96.
10. Possett R, et al. 2010. Molecular characterisation of a novel family of cysteine-rich proteins of *Toxoplasma gondii* and ultrastructural evidence of oocyst wall localisation. Int. J. Parasitol. 40:1639–1649.
11. Gajria B, et al. 2008. ToxoDB: an integrated *Toxoplasma gondii* database resource. Nucleic Acids Res. 36:D553–D556.
12. Blake DP, et al. 2012. EmaxDB: availability of a first draft genome sequence for the apicomplexan *Saccharomyces cerevisiae* Mol. Biochem. Parasitol. 184:48–51.
13. Lesage G, Bussey H. 2006. Cell wall assembly in *Saccharomyces cerevisiae*. Mol. Biol. Rev. 70:317–343.
14. Drummond RA, Brown GD. 2011. The role of Dectin-1 in the host defence against fungal infections. Curr. Opin. Microbiol. 14:392–399.
15. Cohen NR, et al. 2011. Innate recognition of cell wall β-glucans drives invariant natural killer T cell responses against fungi. Cell Host Microbe 10:437–450.
16. Eschenauer G, Depested DD, Carver PL. 2007. Comparison of echinocandin antifungals. Ther. Clin. Risk Manag. 3:71–97.
17. Kall L, Krogh A, Sonnhammer EL. 2004. A combined transmembrane topology and signal peptide prediction method. J. Mol. Biol. 338:1027–1036.
18. Marchler-Bauer A, et al. 2011. CDD: a conserved domain database for the functional annotation of proteins. Nucleic Acids Res. 39:D225–D229.
19. Aurrecoechea C, et al. 2007. ApiDB: integrated resources for the apicomplexan bioinformatics resource center. Nucleic Acids Res. 35:D427–D430.
20. Martín-Cuadrado AB, et al. 2008. The Schizosaccharomyces pombe endo-1,3-beta-glucanase Eng1 contains a novel carbohydrate binding module required for septum localization. Mol. Microbiol. 69:188–200.
21. Austin BP, Nallamsetty S, Vaugh DS. 2009. Hexahistidine-tagged maltose-binding protein as a fusion partner for the production of soluble recombinant proteins in *Escherichia coli*. Methods Mol. Biol. 498:157–172.
22. Fetterer RH, Jenkins MC, Miska KB, Cain GD. 2010. Metam sodium reduces viability and infectivity of *Eimeria* oocysts. J. Parasitol. 96:632–637.
23. Dubey JP. 2006. Comparative infectivity of oocysts and bradyzoites of *Toxoplasma gondii* for intermediate (mice) and definitive (cats) hosts. Vet. Parasitol. 140:69–75.
24. Nanduri J, Williams S, Aji T, Flanigan TP. 1999. Characterization of an immunogenic glycocalyx on the surfaces of *Cryptosporidium parvum* oocysts and sporozoites. Infect. Immun. 67:2022–2024.
25. Magnelli PE, Cipollo JF, Robbins PW. 2005. A glucanase-driven fractionation allows redefinition of *Schizosaccharomyces pombe* cell wall composition and structure: assignment of diglucan. Anal. Biochem. 336:202–212.
26. Weiss LM, et al. 1995. A cell culture system for study of the development of *Toxoplasma gondii* bradyzoites. J. Eukaryot. Microbiol. 42:150–157.
27. Knoll LJ, Boothroyd JC. 1998. Molecular biology’s lessons about *Toxoplasma* development: stage-specific homologs. Parasitol. Today 14:490–493.
28. Saeij JP, Arrizabalaga G, Boothroyd JC. 2008. A cluster of four surface antigen genes specifically expressed in bradyzoites, SAG2CDXY, plays an important role in *Toxoplasma gondii* persistence. Infect. Immun. 76:2402–2410.
29. Huynh MH, Carruthers VB. 2009. Tagging of endogenous genes in a *Toxoplasma gondii* strain lacking Ku80. Eukaryot. Cell 8:530–539.
30. Donald RG, Roos DS. 1998. Gene knockouts and allelic replacements in *Toxoplasma gondii*: HXGPR as a selectable marker for hit-and-run mutagenesis. Mol. Biochem. Parasitol. 91:295–305.
31. Rosowski EE, et al. 2011. Strain-specific activation of the NF-kappaB pathway by GRA15, a novel *Toxoplasma gondii* dense granule protein. J. Exp. Med. 208:195–212.
32. Roos DS, Donald RG, Morrissette NS, Moulton AL. 1994. Molecular tools for genetic dissection of the protozoan parasite *Toxoplasma gondii*. Methods Cell Biol. 45:27–63.
33. Bushkin GG, et al. 2010. Suggestive evidence for Darwinian selection against asparagine-linked glycans of *Plasmodium* and *Toxoplasma*. Eukaryot. Cell 9:228–241.